Castle Biosciences (CSTL) News Today $28.45 -0.42 (-1.45%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 20 at 9:17 AM | finance.yahoo.comFrank Stokes Sells 6,923 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockNovember 20 at 5:47 AM | insidertrades.comCastle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive YearNovember 19 at 7:19 AM | finance.yahoo.comCastle Biosciences (NASDAQ:CSTL) Shares Down 7.3% After Insider SellingCastle Biosciences (NASDAQ:CSTL) Shares Down 7.3% After Insider SellingNovember 15, 2024 | marketbeat.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,972 Shares of StockNovember 15, 2024 | insidertrades.comAnalysts Set Castle Biosciences, Inc. (NASDAQ:CSTL) Price Target at $37.88November 15, 2024 | americanbankingnews.comGSA Capital Partners LLP Takes Position in Castle Biosciences, Inc. (NASDAQ:CSTL)GSA Capital Partners LLP acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 51,827 shares of the company'sNovember 14, 2024 | marketbeat.comCastle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings SuggestNovember 12, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Lisanti Capital Growth LLCLisanti Capital Growth LLC lifted its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 60.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 154,710 shares of the company's stock after buying an additNovember 11, 2024 | marketbeat.comPrincipal Financial Group Inc. Purchases 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. lifted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,538,520 shares of the companyNovember 11, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $124,708.92 in StockNovember 8, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by AnalystsShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have earned an average rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price targNovember 8, 2024 | marketbeat.comKornitzer Capital Management Inc. KS Reduces Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Kornitzer Capital Management Inc. KS lowered its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 25.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 407,238 shares of the cNovember 7, 2024 | marketbeat.comResearch Analysts Offer Predictions for CSTL FY2024 EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Research analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of Castle Biosciences in a research note issued on Monday, November 4th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn $0.32 peNovember 7, 2024 | marketbeat.comCastle Biosciences price target raised to $44 from $37 at ScotiabankNovember 6, 2024 | markets.businessinsider.comScotiabank Sticks to Its Buy Rating for Castle Biosciences (CSTL)November 6, 2024 | markets.businessinsider.comCastle Biosciences Faces Financial Strain Amid 2024 Loan Covenant RestrictionsNovember 6, 2024 | markets.businessinsider.comCastle Biosciences price target raised to $36 from $28 at KeyBancNovember 6, 2024 | finance.yahoo.comCastle Biosciences price target raised to $39 from $37 at BairdNovember 6, 2024 | finance.yahoo.comCastle Biosciences Reports Third Quarter 2024 ResultsNovember 6, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | msn.comCastle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 6, 2024 | finance.yahoo.comCastle Biosciences price target raised to $45 from $40 at BTIGNovember 6, 2024 | markets.businessinsider.comCastle Biosciences (CSTL) Gets a Buy from Lake StreetNovember 6, 2024 | markets.businessinsider.comCastle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPSCastle Biosciences (NASDAQ:CSTL - Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The firm had revenue of $85.78 million for the quarter, compared to analysts' expectations of $78.55 million. During the same quarter last year, the company posted ($0.26) EPS.November 5, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Reaches New 52-Week High After Earnings BeatCastle Biosciences (NASDAQ:CSTL) Reaches New 12-Month High on Better-Than-Expected EarningsNovember 5, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Given New $39.00 Price Target at Robert W. BairdRobert W. Baird boosted their price objective on Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comCastle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comCastle Biosciences, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 4, 2024 | seekingalpha.comHarbor Capital Advisors Inc. Acquires 15,200 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Harbor Capital Advisors Inc. increased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 11.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 153,907 shares of the company's stock after puNovember 4, 2024 | marketbeat.comCastle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To ExpectNovember 3, 2024 | finance.yahoo.comCastle Biosciences (NASDAQ:CSTL) Stock Price Down 3.8% - Time to Sell?Castle Biosciences (NASDAQ:CSTL) Shares Down 3.8% - Should You Sell?November 1, 2024 | marketbeat.comCastle Biosciences to present new TissueCypher data at ACG 2024October 30, 2024 | markets.businessinsider.comCastle Biosciences price target raised to $42 from $35 at CanaccordOctober 29, 2024 | markets.businessinsider.comCastle Biosciences (NASDAQ:CSTL) PT Raised to $42.00 at Canaccord Genuity GroupCanaccord Genuity Group upped their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday.October 29, 2024 | marketbeat.comSG Americas Securities LLC Sells 19,330 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)SG Americas Securities LLC lowered its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 71.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,659 shares of theOctober 23, 2024 | marketbeat.comCastle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b TumorsOctober 20, 2024 | businesswire.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $63,636.44 in StockOctober 17, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Sees Significant Drop in Short InterestCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totalling 1,610,000 shares, a drop of 6.4% from the September 15th total of 1,720,000 shares. Based on an average trading volume of 397,400 shares, the days-to-cover ratio is currently 4.1 days.October 16, 2024 | marketbeat.comDerek J. Maetzold Sells 1,972 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,972 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $32.27, for a total transaction of $63,636.44. Following the completion of the transaction, the insider now owns 91,664 shares of the company's stock, valued at $2,957,997.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.October 16, 2024 | marketbeat.comCastle Biosciences’ TissueCypher Gains Buy Rating Due to Market Potential and Medicare ReimbursementOctober 16, 2024 | markets.businessinsider.comLake Street Sticks to Their Buy Rating for Castle Biosciences (CSTL)October 16, 2024 | markets.businessinsider.comCastle Biosciences (NASDAQ:CSTL) Sees Unusually-High Trading Volume Following Analyst UpgradeCastle Biosciences (NASDAQ:CSTL) Sees Strong Trading Volume on Analyst UpgradeOctober 15, 2024 | marketbeat.comCastle Biosciences, Inc.'s (NASDAQ:CSTL) Intrinsic Value Is Potentially 95% Above Its Share PriceOctober 15, 2024 | finance.yahoo.comCastle Biosciences (NASDAQ:CSTL) Sets New 1-Year High After Analyst UpgradeCastle Biosciences (NASDAQ:CSTL) Reaches New 12-Month High on Analyst UpgradeOctober 14, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Recommendation of "Buy" from BrokeragesShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have been given an average rating of "Buy" by the five brokerages that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among brokeragesOctober 14, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Given New $40.00 Price Target at BTIG ResearchBTIG Research upped their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a research report on Monday.October 14, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Up 7.3% - What's Next?Castle Biosciences (NASDAQ:CSTL) Stock Price Up 7.3% - What's Next?October 11, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 986 Shares of StockOctober 11, 2024 | insidertrades.comCastle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the SkinOctober 11, 2024 | businesswire.com Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. CSTL Media Mentions By Week CSTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼0.410.46▲Average Medical News Sentiment CSTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼84▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Myriad Genetics News Renalytix News Veracyte News Surgery Partners News LifeStance Health Group News Concentra Group Holdings Parent News PACS Group News Privia Health Group News Ardent Health Partners News Addus HomeCare News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSTL Stock Alerts